Show simple item record

dc.contributor.authorDíaz-Prado, Silvia
dc.contributor.authorMuiños-López, Emma
dc.contributor.authorHermida Gómez, Tamara
dc.contributor.authorCicione, Claudia
dc.contributor.authorRendal Vázquez, María Esther
dc.contributor.authorFuentes Boquete, Isaac Manuel
dc.contributor.authorDe-Toro, Javier
dc.contributor.authorBlanco García, Francisco J
dc.date.accessioned2015-06-16T10:46:18Z
dc.date.available2015-06-16T10:46:18Z
dc.date.issued2011-02-19
dc.identifier.citationDíaz-Prado S, Muíños-López S, Hermida-Gómez T, Ciccione C, Rendal-Vázquez ME, Fuentes-Boquete I, et al. Human amniotic membrane as an alternative source of stem cells for regenerative medicine. Differentiation. 2011;81(3):162-171.es_ES
dc.identifier.urihttp://hdl.handle.net/2183/14683
dc.description.abstract[Abstract] The human amniotic membrane (HAM) is a highly abundant and readily available tissue. This amniotic tissue has considerable advantageous characteristics to be considered as an attractive material in the field of regenerative medicine. It has low immunogenicity, anti-inflammatory properties and their cells can be isolated without the sacrifice of human embryos. Since it is discarded post-partum it may be useful for regenerative medicine and cell therapy. Amniotic membranes have already been used extensively as biologic dressings in ophthalmic, abdominal and plastic surgery. HAM contains two cell types, from different embryological origins, which display some characteristic properties of stem cells. Human amnion epithelial cells (hAECs) are derived from the embryonic ectoderm, while human amnion mesenchymal stromal cells (hAMSCs) are derived from the embryonic mesoderm. Both populations have similar immunophenotype and multipotential for in vitro differentiation into the major mesodermal lineages, however they differ in cell yield. Therefore, HAM has been proposed as a good candidate to be used in cell therapy or regenerative medicine to treat damaged or diseased tissues.es_ES
dc.description.sponsorshipThis study was supported by grants: Servizo Galego de Saúde, Xunta de Galicia (PS07/84), Cátedra Bioiberica de la Universidade da Coruña and Instituto de Salud Carlos III CIBER BBN CB06-01-0040; Ministerio Ciencia en Innovacion PLE2009-0144; Fondo Investigacion Sanitaria-PI 08/2028 with participation of fundus from FEDER (European Community), Silvia Diaz-Prado is beneficiary of an Isidro Parga Pondal contract from Xunta de Galicia, A Coruna, Spain.es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; CB06-01-0040
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MICINN/Programa Nacional de Internacionalización de la I+D/PLE2009-0144/ES/In situ Tissue Engineering using Stem Cells and Functional Biomaterials to Repair Articular Cartilage: An ''in Vivo Model"
dc.description.sponsorshipXunta de Galicia; PS07/84
dc.description.sponsorshipInstituto de Salud Carlos III; PI 08/2028
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.urihttp://dx.doi.org/10.1016/j.diff.2011.01.005es_ES
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 4.0 International Licence (CC-BY-NC-ND 4.0)es_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAmniotic membranees_ES
dc.subjectMesenchymal stem celles_ES
dc.subjectCartilagees_ES
dc.subjectOsteoarthritises_ES
dc.subjectDifferentiation pluripotentes_ES
dc.subjectAmnionderived cellses_ES
dc.titleHuman amniotic membrane as an alternative source of stem cells for regenerative medicinees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record